TECHWIRE 30
(CIX: WRAL30)  1,091.68    (0 %)  Updated: 08:10 PM EDT, Oct 30 2014
(NQ: Apple)  106.98    (0 %)  Updated: 08:10 PM EDT, Oct 30 2014
(NY: QUINTILES)  56.30    (0 %)  Updated: 07:12 PM EDT, Oct 30 2014
(OP: BASF SE)  86.92    (0 %)  Updated: 08:10 PM EDT, Oct 30 2014
(NQ: BioCryst)  12.06    (0 %)  Updated: 08:10 PM EDT, Oct 30 2014
(NQ: BioDelivery)  17.79    (0 %)  Updated: 08:10 PM EDT, Oct 30 2014
(NQ: CEMP)  13.69    (0 %)  Updated: 08:10 PM EDT, Oct 30 2014
(NQ: Cisco Systems)  24.08    (0 %)  Updated: 08:10 PM EDT, Oct 30 2014
(NQ: Cree)  31.51    (0 %)  Updated: 08:10 PM EDT, Oct 30 2014
(NQ: DARA)  0.88    (0 %)  Updated: 08:10 PM EDT, Oct 30 2014
(NY: EMC CORPORATION)  28.46    (0 %)  Updated: 07:12 PM EDT, Oct 30 2014
(NQ: Extreme Networks)  3.53    (0 %)  Updated: 08:10 PM EDT, Oct 30 2014
(NQ: FB)  74.11    (0 %)  Updated: 08:10 PM EDT, Oct 30 2014
(NY: GLAXOSMITHKLINE)  45.14    (0 %)  Updated: 07:12 PM EDT, Oct 30 2014
(NQ: GOOG)  550.31    (0 %)  Updated: 08:10 PM EDT, Oct 30 2014
(NY: IBM)  164.35    (0 %)  Updated: 07:12 PM EDT, Oct 30 2014
(NY: LH)  107.39    (0 %)  Updated: 07:12 PM EDT, Oct 30 2014
(OP: Lenovo Group)  29.56    (0 %)  Updated: 08:10 PM EDT, Oct 30 2014
(NY: MRK)  57.31    (0 %)  Updated: 07:12 PM EDT, Oct 30 2014
(NQ: Microsoft Corp)  46.05    (0 %)  Updated: 08:10 PM EDT, Oct 30 2014
(NQ: NTAP)  42.11    (0 %)  Updated: 08:10 PM EDT, Oct 30 2014
(NY: NOVARTIS AG)  91.95    (0 %)  Updated: 07:12 PM EDT, Oct 30 2014
(OP: Novozymes A/S)  46.31    (0 %)  Updated: 08:10 PM EDT, Oct 30 2014
(NY: PFIZER)  29.84    (0 %)  Updated: 07:12 PM EDT, Oct 30 2014
(NQ: Pozen)  9.17    (0 %)  Updated: 08:10 PM EDT, Oct 30 2014
(NY: RED HAT)  58.25    (0 %)  Updated: 07:12 PM EDT, Oct 30 2014
(NQ: BBRY)  10.48    (0 %)  Updated: 08:10 PM EDT, Oct 30 2014
(NQ: Salix)  144.50    (0 %)  Updated: 08:10 PM EDT, Oct 30 2014
(NQ: SQI)  16.93    (0 %)  Updated: 08:10 PM EDT, Oct 30 2014

Posts tagged “GSK”

Updated October 24

GSK exec on Ebola vaccine trial: 'We only have one shot to get this right'

Ebola The World Health Organization says millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines will start being tested in March. And GSK is ramping up vaccine trial. Paul Allen chips in $100 million. But will all this be enough to stop Ebola?

October 22

Witty defends himself, GSK: 'Look at what we're able to achive'

Having been fined nearly $500 million in China for bribery, facing investigations in other countries and battling lagging revenue, GSK now faces more cost cuts and is contemplating a stock offering for its ViiV Healthcare. But GSK's CEO Andrew Witty defended himself and his strategy in discussing the drug giant's most recent quarterly earnings report on Wednesday. "Look at what we're able to achieve," he says.

GSK's Andrew Witty talks strategy GSK's Andrew Witty talks strategy

October 21

GSK's Ebola vaccine could be tested in January, WHO says

Ebola Tens of thousands of doses of experimental Ebola vaccines -including one from GlaxoSmithKline - could be available for "real-world" testing in West Africa as soon as January as long as they are deemed safe, a top World Health Organization official said Tuesday.

Updated October 17

Exec: GSK's Ebola vaccine will 'come too late' for current epidemic

Ebola The head of Ebola vaccine research at GlaxoSmithKline tells the BBC that the company's treatment that is now being tested isn't likely to be "the primary answer to this particular outbreak." He concedes GSK could have moved faster.

Updated October 8

Lenovo class-action suit; new GSK probe; AT&T data breach; Salix drug wins OK; Facebook's anonymous app; Lenovo-NEC deal

Bulldog In today's Bulldog blog wrapping up the latest technology and life science news: Lenovo settles a class-action suit over Wi-Fi; GSK faces another bribery investigation; AT&T data breach; FDA OKs Salix colitis treatment; Facebook is developing an app for anonymous posts; and Lenovo extends its partnership with NEC.

September 30

Premium Lock GSK pledges $5M for startups; UNC, Duke scientists land grants for BRAIN Initiative

President Obama's BRAIN Initiative - Brain Research through Advancing Innovative Neurotechnologies - second year kickoff includes three RTP connections: Funding from GlaxoSmithKline and research grants for teams at UNC-Chapel Hill as well as Duke.

An NIH look at the brain  An NIH look at the brain

September 25

Premium Lock GSK confirms bank exec to take over as board chairman

GSK  Drug giant GlaxoSmithKline will have a new chairman a year from now: Philip Hampton, the current chair at Royal Bank of Scotland Group. Hampton will first join the GSK board as of Jan. 1 as a director.

Updated September 25

Premium Lock New GSK chairman; Lenovo stock pressure; FTC bitcoin crackdown; FAA to OK drones; Cree's new competition

Bulldog In today's wrapup of life science and technology news: GSK is getting a new chairman in wake of the China bribery scandal, says The Times of London; Lenovo stock faces price pressure; FTC takes aim at bitcoins; FAA to OK drones for Hollywood; Cree's new competition from Philips.

Updated September 19

Premium Lock GSK China exec convicted, drug giant fined $492M in bribery scandal

GSK in China  A former executive of drugmaker GlaxoSmithKline and four Chinese co-defendants have been sentenced to prison in a bribery case but may never have to serve that time. GSK also issued an apology.

September 19

Premium Lock 'GSK sincerely apologizes' in statement after scandal verdict

Through its GSK China website, the drug giant formally apologized to the Chinese government and people for "illegal activities" that led to a $492 million fine and conviction of its top executive in that country. The full statement follows.

GSK's apology on front page of its China website GSK's apology on front page of its China website

August 29

Premium Lock US to begin tests of GSK's Ebola vaccine next week

The National Institutes of Health announced Thursday that it is launching the safety trial on a vaccine developed by the agency's National Institute of Allergy and Infectious Diseases and GlaxoSmithKline. Beginning Tuesday, it will test 20 healthy adult volunteers to see if the virus is safe and triggers an adequate response in their immune systems.

Ebola virus     Ebola virus

Updated August 28

Premium Lock US to test GSK's vaccine for Ebola; Greenville lab could produce a treatment

A possible vaccine to treat the spreading Ebola outbreak in Africa could be coming from GSK. Plus, a lab in Greenville could be a site where a treatment is produced.

Ebola virus     Ebola virus

Updated August 14

Premium Lock Duke doctor warns against use of untested Ebola drugs

As more companies step up efforts to develop vaccines targeting ebola and the disease outbreak spreads in Africa, a doctor at Duke University warns that using untested drugs "could prove disastrous."

Updated August 12

Premium Lock Wall Street Journal report questions investor confidence in GSK's CEO

Another day, another headache in the global press for GlaxoSmithKline and its CEO Andrew Witty. This time it's an in-depth report in The Wall Street Journal in which some investors question Witty's performance as the drug giant fights lagging sales and scandal.

Updated August 11

Premium Lock GSK could have first ebola vaccine in 2015, world health official says

A World Health Organization official says the first ebola vaccine could be available in 2015. It's being developed by GlaxoSmithKline. However, the drug giant says "it's too early" to speculate on timing.

Ebola fight   Ebola fight

August 11

Premium Lock GSK-hired investigators face jail time; son blames Glaxo

China business   "The root of the problem really from where I'm sitting is the way GSK behaved in this matter," the son of convicted investigator tells London-based broadcaster Sky News. GSK has said it hired the couple to investigate a security breach but not bribery allegations.

Tags: GSK
August 8

Premium Lock Trial of British-US couple with Glaxo ties continues in China

China business   Peter Humphrey and Yingzeng Yu worked under contract for British pharmaceutical giant GlaxoSmithKline, which is accused in a separate case of bribing Chinese doctors and hospitals to use its products. Authorities have not indicated whether these two cases are linked as the fraud trial continues in China.

August 6

Premium Lock Latest news on Glaxo, Comcast, FCC and Google

Bulldog In the latest Bulldog roundup of life science and technology news: GSK gets a lift as Express Scripts reinstates lung drug Advair; Comcast initiates amnesty, free service for the poor; FCC's Friends and Family Plan; and Wikipedia link to be hidden in Google under 'right to be forgotten' law.

Updated August 5

Premium Lock Latest news on Microsoft, Apple, GSK, municipal broadband, Google and MCS

Bulldog In the latest Bulldog roundup of life science and technology news: The real difference between Microsoft and Apple; Novo Nordisk leapfrogs Glaxo as U.K. drug giant declines; U.S. Map shows more community-owned broadband networks than expected; Google email scan leads to sex offender arrest; and Metrics Contract Services adopt new name and logo.

July 29

Premium Lock China to put GSK-hired investigators on trial Aug. 8

GSK China's web page  A Shanghai court says American and British investigators who worked for drug maker GlaxoSmithKline will stand trial Aug. 8 on charges of illegally obtaining information on Chinese citizens.

Techwire Inside Partners
The Skinny: A Blog by Rick Smith

OUR INSIDERS

Vivek Wadhwa
Commentary
Frank Vinluan
Life science
Dr. Mike Walden
Tech economy
Scroll